Trevi Therapeutics Stock Investor Sentiment

TRVI Stock  USD 2.82  0.06  2.08%   
Under 66% of Trevi Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that many investors are alarmed at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
  

Trevi Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Trevi Therapeutics to Participate in Upcoming April Events
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Sandell Scott D of 948948 shares of Trevi Therapeutics at 1.9 subject to Rule 16b-3
Macroaxis News
over six months ago at investing.com         
Trevi Therapeutics appoints new VP for clinical development
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Yahoo News
over six months ago at news.google.com         
Brokers Issue Forecasts for Trevi Therapeutics, Inc.s FY2025 Earnings - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Trevi Therapeutics, Inc. Q4 2023 Earnings Call Transcript
Yahoo News
over six months ago at insidermonkey.com         
Trevi Therapeutics, Inc. Q4 2023 Earnings Call Transcript
insidermonkey News
over six months ago at investorplace.com         
TRVI Stock Earnings Trevi Therapeutics Beats EPS for Q4 2023
sbwire news
over six months ago at gurufocus.com         
Trevi Therapeutics Inc Announces Year-End Financials and Progress in Clinical Trials
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business ...
Yahoo News
over six months ago at simplywall.st         
Institutional investors control 36 percent of Trevi Therapeutics, Inc. and were rewarded last week a...
Simply Wall St News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 7271 shares by Tpg Gp A, Llc of Trevi Therapeutics at 2.7699 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Trevi Therapeutics Set to Announce Quarterly Earnings on Wednesday - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Trevi Therapeutics Releases Earnings Results, Beats Estimates By 0.09 EPS - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update o...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Trevi Therapeutics that are available to investors today. That information is available publicly through Trevi media outlets and privately through word of mouth or via Trevi internal channels. However, regardless of the origin, that massive amount of Trevi data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Trevi Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Trevi Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Trevi Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Trevi Therapeutics alpha.

Trevi Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 4219 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/06/2024
2
Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/09/2024
3
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
09/26/2024
4
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
09/30/2024
5
Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com
10/04/2024
6
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
10/15/2024
7
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.
10/23/2024
8
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/06/2024
9
Trevi Therapeutics, Inc. Q3 2024 Earnings Call Transcript
11/08/2024
10
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow
11/14/2024

Complementary Tools for Trevi Stock analysis

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA